Biogen (BIIB.US) stock has been halted after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.
Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5
US OPEN: Higher CPI Inflation Cools Sentiment, Anthropic Targets $1.4 Trillion Valuation
Anthropic Debut Price. Does One Trillion Dollars Sound Reasonable?
What’s Next for the S&P 500? 🔼 U.S. Earnings Season Recap
US OPEN: Falling Oil Prices and Dip-Buying Fuel Rebound as Nvidia falls